Methyldopa hydrate
Treatment of hypertension, especially pregnancy-induced hypertension
- CAS No.
- 41372-08-1
- Indication Class
- Cardiovascular / Renal
- Patent Expiry
- Off-patent · 1995
- Therapeutic Area
- Cardiovascular / Pregnancy
- Target / Mechanism
- ADRA2A·ADRA2C·ADRA2B
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- Compound patent long expired; mature multi-source generic supply
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A long-standing safe choice for pregnancy hypertension, not affecting the fetus and retained by multiple guideline sets; sustained demand as an essential medicine in emerging markets.
Cardiovascular / Pregnancy · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Methyldopa hydrate is a centrally acting antihypertensive active pharmaceutical ingredient. It lowers blood pressure by inhibiting sympathetic nervous activity and is mainly used for the treatment of hypertension, particularly in pregnancy-induced hypertension. It has a favorable safety profile and extensive clinical use, and is commonly formulated into oral dosage forms such as tablets.
Supply source: Unibest · Methyldopa hydrate, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.